ArticleDermatology and therapy2025
Integrative Proteomics and Genomics Identify Novel Biomarkers and Therapeutic Targets in Vitiligo via Mendelian Randomization.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A synergistic multi-omics approach: causal sepsis drivers identified in activated CD4Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionGiven that the proteome is a major source of therapeutic targets, we conducted a proteome-wide Mendelian randomization (MR) combined with transcriptome sequencing analysis to identify candidate protein markers and therapeutic targets for vitiligo.
methodsBased on protein quantitative trait loci (pQTLs) and genetic associations with vitiligo obtained from the European Bioinformatics Institute (EBI) database (60 vitiligo cases and 402,672 controls), and the UK Biobank (95 vitiligo cases and 337,064 controls), bidirectional MR and colocalization analyses identified genetically predicted levels of nine proteins collectively linked to vitiligo risk. Based on the RNA-seq data and single-cell RNA-seq data of vitiligo, bioinformatics analysis and model prediction of genes associated with vitiligo progression evaluated the relationship between candidate core proteins and the development of vitiligo.
resultsFour proteins (KLF4, MYL4, TNFRSF13C, TNFSF13B) were associated with lower vitiligo risk, while five proteins (ALPI, CDH1, ITGB1, SERPINH1, TNFSF10) were linked to higher risk. Of these, three proteins (KLF4, TNFRSF13C, and TNFSF10) were high priority with the most convincing evidence. Bioinformatics analysis and model prediction of genes associated with vitiligo progression showed these three protein-coding genes were significantly associated with vitiligo occurrence, and their functions were related to cell cycle, apoptosis, oxidative stress, inflammatory response, and immune infiltration. Mechanistically, the expression of these key candidate molecules was regulated by various miRNAs and transcription factors. The druggability assessment and molecular docking identified some drugs targeting these proteins, such as APTO-2535 and butyric acid.
conclusionKLF4, TNFRSF13C, and TNFSF10 may be involved in regulating the occurrence and development of vitiligo, providing potential targets for improving the diagnosis and treatment of vitiligo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.